Case Reports in the Journal of the American College of Cardiology Underscore the Critical Role of Blood Volume Analysis in Optimizing Heart Failure Treatment
Tag: Daxor
New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care
Research Published in the Prestigious Journal of Cardiac Failure From Three Institutions
DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)
The Premier Event for Cardiovascular Industry Leaders and Clinicians
Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering
Oak Ridge, TN, June 22, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announced that Maxim Group LLC (“Maxim”), as Representative of several Underwriters of its previously announced secondary public offering have partially exercised their option to purchase an additional 54,339 Option Shares […]
Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering
Oak Ridge, TN, May 25, 2023 (GLOBE NEWSWIRE) — DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the closing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 […]
Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering
Oak Ridge, TN, May 22, 2023 (GLOBE NEWSWIRE) — DAXOR CORPORATION (Nasdaq: DXR) (“Daxor”, or the “Company”), the global leader in blood volume measurement technology, today announced the pricing of its previously announced underwritten public offering of 410,260 shares of its common stock at a public offering price of $9.75 […]
New Study Demonstrates Clinical Utility of Daxor’s Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes
Daxor’s BVA Technology Shown to Provide Unique and Individualized Data for Patient Management Oak Ridge, TN, May 18, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces new data demonstrating the importance and clinical utility of Daxor’s BVA-100 blood test in heart failure […]
Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients
Oak Ridge, TN, March 27, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement technology, today announces five new hospitals have implemented the Company’s BVA-100 blood volume diagnostic for clinical use to guide fluid management in heart failure patients during the first quarter of 2023. The addition […]
Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders
Oak Ridge, TN, March 03, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today issued a corporate update in a Letter to Shareholders filed in its certified shareholder report on Form N-CSR on March 1, 2023 from CEO & President, Michael Feldschuh. Dear Fellow […]
Daxor Corporation Reports a 37% Increase in NAV to $6.75 Per Share for the Year Ended December 31, 2022
Conference Call to be held today at 9:00 AM EST Oak Ridge, TN, March 02, 2023 (GLOBE NEWSWIRE) — Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, filed its Annual Report to Shareholders on Form N-CSR on March 1, 2023, disclosing its schedule of portfolio holdings as of December […]
